Sodium Salicylate

HCID 16760658

ノート反応

部分構造検索類似構造を探す

基本情報

CAS: 54-21-7
標準SMILES: O=C([O-])c1ccccc1O.[Na+]
InChIKey: ABBQHOQBGMUPJH-UHFFFAOYSA-M
分子式: C7H5NaO3
平均分子量: 160.1 g/mol
単同位体質量: 160.0136383

概要

Sodium salicylate is an organic molecular entity.

名称と識別子

優先名称: Sodium Salicylate
IUPAC: sodium 2-hydroxybenzoate
英語名: Benzoic acid, 2-hydroxy-, monosodium salt, coupled with 4-amino-5-hydroxy-2,7-naphthalenedisulfonic acid, diazotized 2-(4-aminophenyl)-1H-benzimidazol-5-amine and diazotized 4-nitrobenzenamine, sodium salt
分子式: C7H5NaO3
分子量: 160.10257

名称と別名

Sodium salicylate54-21-7EnterosalicylKerasalicylAlysineBenzoic acid, 2-hydroxy-, monosodium saltNatrum salicylicumSalicylic acid sodium saltsalicylate sodiumDTXSID5021708Monosodium 2-hydroxybenzoateNatrii salicylas

名称をさらに表示

Benzoic acid, 2-hydroxy-, monosodium salt, coupled with 4-amino-5-hydroxy-2,7-naphthalenedisulfonic acid, diazotized 2-(4-aminophenyl)-1H-benzimidazol-5-amine and diazotized 4-nitrobenzenamine, sodium salt

WIQ1H85SYPSalicylate, sodiumNSC-202167DTXCID701708Benzoic acid, 2-hydroxy-, sodium salt (1:1)NSC202167Sod salPro-Prin

データベース識別子

CAS: 54-21-7、90218-94-3
PubChem CID: 16760658
DTXSID: DTXSID5021708
ChEMBL: CHEMBL447868
ChEBI: CHEBI:9180
UNII: WIQ1H85SYP
EC Number: 200-198-0、290-774-8

物性

構造計算による物性

極性表面積: 60.4 Å²
水素結合供与体数: 1
水素結合受容体数: 3
回転可能結合数: 1
重原子数: 11
形式電荷: 0
複雑度: 138

実験および物理化学的性質

Cosmetics · 2 件

Cosmetic ingredients (Sodium Salicylate) -> CIR (Cosmetic Ingredient Review)

Preservative

Animal DrugsPharmaceuticals -> UK Veterinary Medicines Directorate List

Food Contact Substances · 4 件

FCS -> FDA Cumulative Estimated Daily Intake (CEDI)

FCS -> FDA Inventory of Food Contact Substances Listed in 21 CFR

FCS -> FDA Inventory of Effective Food Contact Substance (FCS) Notifications

Physical DescriptionDry Powder

安全と法規制

GHS分類

GHS Classification · 6 件

This chemical does not meet GHS hazard criteria for 0.7% (3 of 441) of reports.

Warning

H302 (96.4%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P264+P265, P270, P280, P301+P317, P305+P351+P338, P318, P330, P337+P317, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 441 reports by companies from 22 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

危険有害性情報

Regulatory Information · 4 件

Chemical: Benzoic acid, 2-hydroxy-, sodium salt (1:1)

Benzoic acid, 2-hydroxy-, sodium salt (1:1) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Benzoic acid, 2-hydroxy-, sodium salt (1:1) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)

Status: Active Update: 17-06-2020 https://echa.europa.eu/registration-dossier/-/registered-dossier/13593

Sodium salicylate: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Salicylic acid and its salts: Human health tier II assessment

Hazard Classes and Categories · 2 件

Acute Tox. 4 (96.4%)

Acute toxicity - category 4

毒性情報

Toxicity Summary · 2 件

The Panel concluded that the following ingredients are safe in cosmetics in the present practices of use and concentration described in the safety assessment, when formulated to be non-irritating and non-sensitizing, which may be based on a quantitative risk assessment (QRA)...Sodium Salicylate...

Safe for use in cosmetics, with qualifications

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

MeSH Pharmacological Classification · 2 件

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.